Results 11 to 20 of about 38,769 (305)
SGLT2 Inhibitors and the Diabetic Kidney [PDF]
Diabetes Care, 2016 Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may ...
FIORETTO, PAOLA +4 more
openaire +4 more sources
Development of SGLT1 and SGLT2 inhibitors [PDF]
Diabetologia, 2018 Sodium-glucose cotransporters SGLT1 (encoded by SGLT1, also known as SLC5A1) and SGLT2 (encoded by SGLT2, also known as SLC5A2) are important mediators of epithelial glucose transport. While SGLT1 accounts for most of the dietary glucose uptake in the intestine, SGLT2 is responsible for the majority of glucose reuptake in the tubular system of the ...
Timo Rieg, Volker Vallon
openaire +6 more sources
Renoprotective Effects of SGLT2 Inhibitors [PDF]
Heart Failure Clinics, 2022 SGLT2 inhibitors can protect the kidneys of patients with and without type 2 diabetes from failing. This includes blood glucose dependent and independent mechanisms. SGLT2 inhibitors lower glomerular pressure and filtration, thereby reducing the physical stress on the filtration barrier and the oxygen demand for tubular reabsorption.
Vallon, Volker
openaire +5 more sources
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
Medicina, 2023 There is a need for innovative pharmaceutical intervention in light of the increasing prevalence of metabolic disease and cardiovascular disease. The kidneys’ sodium-glucose cotransporter 2 inhibitors (SGLT2) receptors are targeted to reduce glucose ...
Munteanu Madalina Andreea +6 more
doaj +2 more sources
Cardiovascular Diabetology, 2020 Background Clinical trials have shown the cardiovascular protective effect of sodium–glucose cotransporter-2 (SGLT2) inhibitors and reduced hospitalization for heart failure. However, no study has investigated the association between SGLT2 inhibitors and
Hung-Yi Chen +3 more
doaj +1 more source
The Role of SGLT2 Inhibitors in Atherosclerosis: A Narrative Mini-Review [PDF]
, 2021 Objective: Sodium glucose cotransporter 2 inhibitors (SGLT2-is) are antidiabetic drugs that improve glycemic control by limiting urinary glucose reuptake in the proximal tubule.
Salvador, Dante Jr. +5 more
core +1 more source
Cardiovascular Diabetology, 2020 Background Sodium glucose cotransporter 2 (SGLT2) inhibitors have shown greater reductions of cardiovascular event risks than dipeptidyl peptidase-4 (DPP4) inhibitors, whereby possible mechanisms may involve the better pleiotropic effects of SGLT2 ...
Shih-Chieh Shao +7 more
doaj +1 more source
SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
Frontiers in Cardiovascular Medicine, 2020 Three cardiovascular outcome trials of sodium glucose cotransporter 2 (SGLT2) inhibitors, including the EMPA-REG OUTCOME trial, CANVAS Program, and DECLARE TIMI 58 trial, revealed that SGLT2 inhibitors were superior to a matching placebo in reducing ...
Yasuhiro Maejima
doaj +1 more source
Diabetic ketoacidosis with SGLT2 inhibitors [PDF]
BMJ, 2020 ### What you need to know A 45 year old woman with type 2 diabetes complains of malaise, shortness of breath, and nausea for two days. She has been taking metformin and insulin. She was started on canagliflozin six weeks earlier to improve glycaemic control. Over the previous week she has halved the insulin dose. On examination, she is drowsy.
Giovanni, Musso +3 more
openaire +2 more sources
International Journal of Cardiology: Heart & Vasculature, 2022 Background: Recent clinical trials have shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors have beneficial effects on renal function in heart failure patients. This study confirmed the renoprotective effect of treatment with SGLT2 inhibitors in
Go Yokouchi +11 more
doaj +1 more source